MINI-REVIEW: Blood Oxylipin Profiles as Markers of Oncological Diseases

---

Dmitry V. Chistyakov^1,a*, Ludmila V. Kovalenko², Maxim Y. Donnikov², and Marina G. Sergeeva²

¹Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia

²Medical Institute, Surgut State University, 628416 Surgut, Russia

^* To whom correspondence should be addressed.

Received November 1, 2022; Revised March 3, 2023; Accepted March 11, 2023

---

Oxylipins are signal lipid molecules formed from polyunsaturated fatty acids (PUFAs) in several multienzymatic metabolic pathways, such as cyclooxygenase (COX), lipoxygenase (LOX), epoxygenase (CYP), and anandamide pathways, as well as non-enzymatically. The pathways of PUFA transformation are activated in parallel, yielding a mixture of physiologically active substances. Although the association of oxylipins with carcinogenesis had been established a long time ago, only recently analytical methods have advanced to a degree allowing detection and quantification of oxylipins from different classes (oxylipin profiles). The review describes current approaches to the HPLC-MS/MS analysis of oxylipin profiles and compares oxylipin profiles from patients with oncological diseases (breast cancer, colorectal cancer, ovarian cancer, lung cancer, prostate cancer, liver cancer). The possibility of using blood oxylipin profiles as biomarkers in oncological diseases is discussed. Understanding the patterns of PUFA metabolism and physiological activity of combinations of oxylipins will improve early diagnostics of oncological diseases and evaluation of disease prognosis.

---

KEY WORDS: oxylipins, eicosanoids, oncology, metabolomics, lipid profile, polyunsaturated fatty acids

DOI: 10.1134/S000629792305005X

---